Liquidia Technologies (LQDA) Granted FDA Tentative Approval for YUTREPIA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Liquidia Technologies (LQDA) PT Lowered to $29 at H.C. Wainwright
August 20, 2024 6:12 AM EDTH.C. Wainwright analyst Andrew S. Fein lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $29.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Patent attorney's thoughts on competitor's patent exclusivity. From our conversations with a patent attorney, in terms of the patent exclusivity that was recently granted to Tyvasao, it is important to note that there are various types of exclusivity under the Hatch-Waxman Act. The New Chemical Entity (NCE) exclusivity ran out on Treprostinil five years after Remodulin was approved and only one NCE exclusivity is granted per... More
Liquidia Technologies (LQDA) PT Lowered to $23 at BofA Securities
August 20, 2024 4:56 AM EDTBofA Securities analyst Greg Harrison lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $23.00 (from $24.00) while maintaining a Buy rating.
The analyst comments "We update our LQDA PO to $23/shr (from $24) based on todays update the FDA will issue final Yutrepia... More
Liquidia Technologies (LQDA) PT Lowered to $17 at Jefferies
August 19, 2024 4:01 PM EDTJefferies analyst Kambiz Yazdi lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $17.00 (from $22.00) while maintaining a Buy rating.
The analyst comments "Tentative approval for Yutrepia in PAH and now PH-ILD was tempered by simultaneous grant of regulatory exclusivity for Tyvaso DPI until... More
Liquidia Technologies (LQDA) PT Lowered to $25 at BTIG
August 19, 2024 11:15 AM EDTBTIG analyst Julian Harrison lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $25.00 (from $29.00) while maintaining a Buy rating.
The analyst comments "Three-year New Clinical Investigation (NCI) Exclusivities are typically granted by the FDA soon after approval, making todays update unusual since Tyvaso DPI (UTHR, Neutral) has been approved since May 2022. 75% of... More
